Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
Top Cited Papers
Open Access
- 31 July 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 138 (5), 458-468
- https://doi.org/10.1161/circulationaha.118.034222
Abstract
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. Methods: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF. Results: Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all PP0.130), except for a possibly reduced absolute rate of events attributable to osmotic diuresis among those with a prior history of HF (P=0.03). Conclusions: In patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized HF across a broad range of different patient subgroups. Benefits may be greater in those with a history of HF at baseline. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754.This publication has 28 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Worldwide access to treatment for end-stage kidney disease: a systematic reviewThe Lancet, 2015
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million peopleThe Lancet Diabetes & Endocrinology, 2014
- Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trialsNutrition, Metabolism and Cardiovascular Diseases, 2014
- Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysisEuropean Heart Journal, 2013
- Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiologyDiabetes and Vascular Disease Research, 2013
- Endothelial Dysfunction, Arterial Stiffness, and Heart FailureJournal of the American College of Cardiology, 2012
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line AgentsJAMA, 2003